121 related articles for article (PubMed ID: 15599937)
1. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part I-lymphoma.
Featherstone C; Delaney G; Jacob S; Barton M
Cancer; 2005 Jan; 103(2):383-92. PubMed ID: 15599937
[TBL] [Abstract][Full Text] [Related]
2. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma.
Featherstone C; Delaney G; Jacob S; Barton M
Cancer; 2005 Jan; 103(2):393-401. PubMed ID: 15593373
[TBL] [Abstract][Full Text] [Related]
3. Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines.
Delaney G; Jacob S; Barton M
Cancer; 2006 Jan; 106(2):453-65. PubMed ID: 16355366
[TBL] [Abstract][Full Text] [Related]
4. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines.
Delaney G; Jacob S; Featherstone C; Barton M
Cancer; 2005 Sep; 104(6):1129-37. PubMed ID: 16080176
[TBL] [Abstract][Full Text] [Related]
5. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium.
Delaney G; Jacob S; Barton M
Cancer; 2004 Aug; 101(4):682-92. PubMed ID: 15305397
[TBL] [Abstract][Full Text] [Related]
6. Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies.
Delaney G; Jacob S; Barton M
Cancer; 2005 Feb; 103(3):462-73. PubMed ID: 15612081
[TBL] [Abstract][Full Text] [Related]
7. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I--malignancies of the cervix, ovary, vagina and vulva.
Delaney G; Jacob S; Barton M
Cancer; 2004 Aug; 101(4):671-81. PubMed ID: 15305396
[TBL] [Abstract][Full Text] [Related]
8. Estimation of an optimal radiotherapy utilization rate for melanoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2004 Mar; 100(6):1293-301. PubMed ID: 15022299
[TBL] [Abstract][Full Text] [Related]
9. Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2004 Aug; 101(4):657-70. PubMed ID: 15305395
[TBL] [Abstract][Full Text] [Related]
10. Estimation of an optimal radiotherapy utilization rate for breast carcinoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2003 Nov; 98(9):1977-86. PubMed ID: 14584082
[TBL] [Abstract][Full Text] [Related]
11. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma.
Delaney G; Jacob S; Barton M
Cancer; 2005 Jun; 103(11):2216-27. PubMed ID: 15856428
[TBL] [Abstract][Full Text] [Related]
12. Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines.
Delaney G; Shafiq J; Chappell G; Barton M
Cancer; 2008 May; 112(9):1912-22. PubMed ID: 18318431
[TBL] [Abstract][Full Text] [Related]
13. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
14. Estimation of an optimal utilisation rate for palliative radiotherapy in newly diagnosed cancer patients.
Jacob S; Wong K; Delaney GP; Adams P; Barton MB
Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):56-64. PubMed ID: 19969443
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
16. A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003.
Jezersek Novaković B; Vovk M; Juznic Setina T
Ann Hematol; 2006 Dec; 85(12):849-56. PubMed ID: 16944146
[TBL] [Abstract][Full Text] [Related]
17. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
18. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
[TBL] [Abstract][Full Text] [Related]
19. Treatment and survival for non-Hodgkin's lymphoma: influence of histological subtype, age, and other factors in a population-based study (1999-2001).
Cronin-Fenton DP; Sharp L; Deady S; Comber H
Eur J Cancer; 2006 Nov; 42(16):2786-93. PubMed ID: 16930993
[TBL] [Abstract][Full Text] [Related]
20. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004.
Pulte D; Gondos A; Brenner H
J Natl Cancer Inst; 2008 Sep; 100(18):1301-9. PubMed ID: 18780868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
